- Home
- PROK vs NHS Comparison
PROK vs NHS Comparison
Compare PROK & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- NHS
- Stock Information
- Founded
- PROK 2015
- NHS 2003
- Country
- PROK United States
- NHS United States
- Employees
- PROK 163
- NHS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- NHS Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- NHS Finance
- Exchange
- PROK Nasdaq
- NHS Nasdaq
- Market Cap
- PROK 212.4M
- NHS 221.6M
- IPO Year
- PROK N/A
- NHS N/A
- Fundamental
- Price
- PROK $1.66
- NHS $7.57
- Analyst Decision
- PROK Buy
- NHS
- Analyst Count
- PROK 5
- NHS 0
- Target Price
- PROK $4.50
- NHS N/A
- AVG Volume (30 Days)
- PROK 566.3K
- NHS 111.8K
- Earning Date
- PROK 11-12-2024
- NHS 01-01-0001
- Dividend Yield
- PROK N/A
- NHS 13.44%
- EPS Growth
- PROK N/A
- NHS N/A
- EPS
- PROK N/A
- NHS N/A
- Revenue
- PROK N/A
- NHS N/A
- Revenue This Year
- PROK N/A
- NHS N/A
- Revenue Next Year
- PROK N/A
- NHS N/A
- P/E Ratio
- PROK N/A
- NHS N/A
- Revenue Growth
- PROK N/A
- NHS N/A
- 52 Week Low
- PROK $1.18
- NHS $6.95
- 52 Week High
- PROK $4.44
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- PROK 46.29
- NHS 42.83
- Support Level
- PROK $1.50
- NHS $7.51
- Resistance Level
- PROK $1.90
- NHS $7.61
- Average True Range (ATR)
- PROK 0.15
- NHS 0.10
- MACD
- PROK -0.01
- NHS 0.01
- Stochastic Oscillator
- PROK 45.45
- NHS 24.32
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.